Why the study?
With the discovery of the nonpeptide agonist C21, examining the significance and beneficial effects of AT2R in pathologies such as obesity, hypertension, kidney disease, and COVID-19 became warranted.
Design
Review summarizing gene knockout and pharmacological studies
Authors
Loading...
AT1R remains central to hypertension care; review leaves open targeted multi-organ therapies beyond current blockers.
This review highlights the emerging therapeutic potential of targeting the Angiotensin II Type 2 Receptor (AT2R) for managing hypertension, metabolic dysfunction, and organ remodeling.
Fatima et al. (2021) studied this question.